Sala de Imprensa
Comunicado de Imprensa

Together we advance PR600

03. janeiro 2022

Investigational New Drug Application for PR600 expected in 3Q 2022.

Prometheus Biosciences and Dr. Falk Pharma advance PR600.

“It is our goal to find solutions that will ultimately help the millions of people living with inflammatory bowel disease and the Prometheus team has been a strong partner with a differentiated approach to help us exceed that goal,” said Roland Greinwald, Ph.D., Managing Director Medicine and Pharmaceutics, Dr. Falk Pharma.

Prometheus Logo

Download Prometheus Biosciences' press release here:

Press release PDF